drugset / Trial / NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Phase 2
Completed
16 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-03
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferasirox | Unknown | — | Oral |
Indications
Burkitt lymphoma
Hodgkins lymphoma
Langerhans cell histiocytosis specific to adulthood
MALT lymphoma
Waldenstrom macroglobulinemia
acute myeloid leukemia with 11q23 abnormalities
acute myeloid leukemia with t(8;21)(q22;q22) translocation
acute undifferentiated leukemia
adult T-cell leukemia/lymphoma
adult acute lymphoblastic leukemia
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
chronic lymphocytic leukemia/small lymphocytic lymphoma
extranodal nasal NK/T cell lymphoma
grade III lymphomatoid granulomatosis
hepatosplenic T-cell lymphoma
intraocular lymphoma
large-cell immunoblastic lymphoma
mantle cell lymphoma
mast cell leukemia
mycosis fungoides and variants
myelodysplastic syndrome associated with isolated del(5q)
myelofibrosis
myeloproliferative neoplasm, unclassifiable
nodal marginal zone B-cell lymphoma
peripheral T-cell lymphoma, not otherwise specified
plasma cell myeloma
primary cutaneous B-cell lymphoma
primary myelofibrosis
small intestine lymphoma
splenic marginal zone lymphoma
testicular lymphoma